Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AIRXPANDERS INCAXP.AX · Entity 159340 | Director · President and CEO | October 26, 2018 | October 30, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AIRXPANDERS INC
Report date October 26, 2018 · Filed October 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.14 · Expires 2028-10-25 | Direct | 2,857,140 |
Reported balance
After 2018-10-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-10-26 · Grant · Acquired 2,857,140 · Balance 2,857,140 F1: 25% of the option shares shall vest one year after the date of hire. Thereafter, the remaining balance of the option shares shall vest in a series of 36 equal consecutive monthly installments until fully vested. |
| Non-qualified Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.14 · Expires 2028-10-25 | Direct | 6,759,987 |
Reported balance
After 2018-10-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-10-26 · Grant · Acquired 6,759,987 · Balance 6,759,987 F1: 25% of the option shares shall vest one year after the date of hire. Thereafter, the remaining balance of the option shares shall vest in a series of 36 equal consecutive monthly installments until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the option shares shall vest one year after the date of hire. Thereafter, the remaining balance of the option shares shall vest in a series of 36 equal consecutive monthly installments until fully vested.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ClearPoint Neuro, Inc.
Report date November 07, 2017 · Filed November 07, 2017
Section 16 reporting ended · disclosed 2017-11-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 147,724 |
Reported balance
After 2017-11-07 transaction · row 1
1 source rowRow 1 · 2017-11-07 · Grant · Acquired 87,500 · Balance 147,724 F1: Shares issued pursuant to that certain Transition, Separation and Consulting Agreement, dated October 6, 2017, by and between the Reporting Person and the Issuer, which was previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 10, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares issued pursuant to that certain Transition, Separation and Consulting Agreement, dated October 6, 2017, by and between the Reporting Person and the Issuer, which was previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 10, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 26, 2018 Filed Oct 30, 2018 19:30 UTC | AIRXPANDERS INC AXP.AX · Entity 159340 | GrantNon-qualified Stock option (right to buy) · Derivative | 6,759,987 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001437749-18-019089 · rdgdoc.xml · derivative · entry 2 Grillo Francis P · CIK 0001619282 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,759,987 Underlying: Common Stock A · 6,759,987 shares Expires 2028-10-25 F1 · derivative.exercise_date: 25% of the option shares shall vest one year after the date of hire. Thereafter, the remaining balance of the option shares shall vest in a series of 36 equal consecutive monthly installments until fully vested. Read SEC document |
| October 26, 2018 Filed Oct 30, 2018 19:30 UTC | AIRXPANDERS INC AXP.AX · Entity 159340 | GrantIncentive Stock Option (right to buy) · Derivative | 2,857,140 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001437749-18-019089 · rdgdoc.xml · derivative · entry 1 Grillo Francis P · CIK 0001619282 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,857,140 Underlying: Common Stock A · 2,857,140 shares Expires 2028-10-25 F1 · derivative.exercise_date: 25% of the option shares shall vest one year after the date of hire. Thereafter, the remaining balance of the option shares shall vest in a series of 36 equal consecutive monthly installments until fully vested. Read SEC document |
| November 07, 2017 Filed Nov 7, 2017 21:33 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 87,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001534424-17-000459 · grillo.xml · nonDerivative · entry 1 Grillo Francis P · CIK 0001619282 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,724 F1 · shares: Shares issued pursuant to that certain Transition, Separation and Consulting Agreement, dated October 6, 2017, by and between the Reporting Person and the Issuer, which was previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 10, 2017. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 20:22 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 15,636 | $0.00 | $0.00 |
DisclosureSEC source: 0001534424-17-000421 · grillo.xml · nonDerivative · entry 1 Grillo Francis P · CIK 0001619282 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,224 F1 · price: The Reporting Person received a portion of his 2016 cash bonus in the form of the Company's common stock based on the closing sales price of the Company's common stock on October 4, 2017. The shares were granted under the Company's Second Amended and Restated 2013 Incentive Compensation Plan. Read SEC document |
| May 26, 2017 Filed May 30, 2017 20:22 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | PurchaseWarrants (right to buy) · Derivative | 12,500 | Not disclosed Strike: $2.20 | Not disclosed |
DisclosureSEC source: 0001534424-17-000240 · grillo.xml · derivative · entry 2 Grillo Francis P · CIK 0001619282 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2022-05-26 F1 · price: The reported securities are included within 12,500 units purchased by the Reporting Person for $2.00 per unit. Each unit consists of one share of common stock and one warrant to purchase one share of common stock. F2 · derivative.exercise_date: The shares subject to this warrant are immediately exercisable. Read SEC document |
| May 26, 2017 Filed May 30, 2017 20:22 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | PurchaseCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001534424-17-000240 · grillo.xml · nonDerivative · entry 1 Grillo Francis P · CIK 0001619282 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,588 F1 · price: The reported securities are included within 12,500 units purchased by the Reporting Person for $2.00 per unit. Each unit consists of one share of common stock and one warrant to purchase one share of common stock. Read SEC document |
| September 02, 2016 Filed Sep 7, 2016 22:36 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | PurchaseWarrants (right to buy) · Derivative | 18,000 | Not disclosed Strike: $5.50 | Not disclosed |
DisclosureSEC source: 0001534424-16-001012 · grillo.xml · derivative · entry 2 Grillo Francis P · CIK 0001619282 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2021-09-02 F1 · price: The reported securities are included within 20,000 units purchased by the Reporting Person for $5.00 per unit. Each unit consis of one share of common stock and one warrant to purchase 0.90 share of common stock. F2 · derivative.exercise_date: The shares subject to this warrant are immediately exercisable. Read SEC document |
| September 02, 2016 Filed Sep 7, 2016 22:36 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | PurchaseCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001534424-16-001012 · grillo.xml · nonDerivative · entry 1 Grillo Francis P · CIK 0001619282 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,088 F1 · price: The reported securities are included within 20,000 units purchased by the Reporting Person for $5.00 per unit. Each unit consis of one share of common stock and one warrant to purchase 0.90 share of common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.